Ambry Genetics

106 articles about Ambry Genetics

• LifeStrands Genomics and Ambry Genetics to Provide Laboratory Testing for Clinical Implementation Pilots in Phase II of Singapore’s National Precision Medicine Programme

  4/19/2023

  LifeStrands Genomics and Ambry Genetics have joined forces to provide clinical genetic testing services in Singapore.

• Unilabs and Ambry Sign Agreement to Enhance Genetic Testing Services for Biopharma Companies in Europe, Latin America and the Middle East

  1/26/2023

  Unilabs, a leading diagnostic services provider, and Ambry Genetics, a leader in clinical diagnostic testing and a subsidiary of REALM IDx, have entered an exclusive partnership to enhance high-quality genetic testing services for government-sponsored and biopharma companies conducting international clinical trials and research.

• Ambry Genetics to Present at 2021 ACMG Annual Clinical Genetics Meeting

  4/13/2021

  Ambry Genetics Corporation announced it will be presenting The Uniform Application of Protein Functional Data has an Impressive Potential to Resolve VUS Rates in BRCA2 based on a study published in The American Journal of Human Genetics in collaboration with researchers at the Mayo Clinic, Moffit Cancer, and the University of Utah.

• Konica Minolta Precision Medicine (KMPM) Company Ambry Genetics Announces Comprehensive COVID-19 Screening, Management, and Testing Program To Help Schools and Businesses to Safely Reopen

  10/1/2020

  The CARE for COVID Program helps employers to make informed decisions about who to test, which test to use, and when to test to help employees return to work safely   [01-October-2020]   ALISO VIEJO, Calif. , Oct. 1, 2020 /PRNewswire/ --  Ambry Genetics  (Ambry), a leading clinical genetic testing lab, is launching its CARE for COVID Program with Western Springs Schoo

• Konica Minolta Precision Medicine (KMPM) Launches Care for COVID Program

  6/29/2020

  The CARE for COVID Program, led by KMPM company Ambry Genetics, helps employers address critical challenges surrounding COVID-19 testing, including helping determine who can return to work, who should be tested, the frequency of employee wellness checks, and test type.

• Ambry Genetics Receives New York State Approval to Offer Paired RNA and DNA Genetic Testing for Hereditary Cancer Risk

  12/16/2019

  +RNAinsight™ is now available for New York patients, and will help identify thousands more patients at increased risk for cancer

• New Data from Ambry Genetics Showed Concurrent RNA and DNA Testing Identified More Patients with Hereditary Breast Cancer than DNA Testing Alone

  12/10/2019

  Separate data demonstrated that finding mutations that increase risks for breast cancer frequently led clinicians to change their medical recommendations to patients.

• New Data from Ambry Genetics Show Substantial Increase in Diagnostic Yield, Further Supporting the Routine Use of RNA Genetic Testing for Hereditary Cancer Panels

  11/5/2019

  Based on data from a prospective, nationwide, multi-center pilot, adding RNA genetic testing to DNA testing identified more disease-causing mutations compared to DNA-only testing.

• New Data from Ambry Genetics Demonstrates Impact of First Major Advancement in Over 10 Years to Increase Diagnostic Yield in Genetic Testing for Hereditary Cancer Risk

  10/15/2019

  In a prospective study, the addition of RNA genetic testing to hereditary cancer panels identified more disease-causing mutations in patients compared to DNA-only testing and clarified inconclusive results.

• Ambry Genetics Makes Scientific Breakthrough and Launches Paired RNA and DNA Testing for Hereditary Cancer

  10/1/2019

  +RNAinsight™ will help identify thousands more patients at increased risk for cancer

• 

  Ambry Genetics Makes Advances in RNA Genetic Testing

  4/11/2019

  Seattle-based Ambry Genetics recently presented data at the American College of Medical Genetics and Genomics annual meeting describing the results of supplemental RNA genetic testing data.

• Ambry Genetics Research Demonstrates RNA Genetic Testing in Hereditary Cancer Improves Variant Classification and Patient Management

  4/5/2019

  Researchers from Ambry Genetics (Ambry), a leading clinical genetics testing company, will present results demonstrating that RNA genetic testing (RGT), as a supplement to DNA genetic testing, improves variant classification in hereditary cancer genetic testing.

• Ambry Genetics to Develop Custom Assays Targeted to Patients with Hereditary Ovarian Cancer

  3/27/2019

  Investigating new testing options to identify patients for clinical trials.

• Invicro and Ambry Genetics Appoint Dr. Kenneth Bloom as Chief Medical Officer of Advanced Pathology and Genomic Services

  6/20/2018

  Precision medicine companies and leading providers of quantitative biomarker and genomic profiling services

• Ambry Genetics and Invicro Announce Partnership to Provide Enhanced Capabilities with Advanced Genomics Services to Enable Precision Medicine

  1/31/2018

  Ambry Genetics Corporation (Ambry), leaders in genetic testing, announced today they will partner with Invicro, a leading provider of imaging services and software for research and drug development, to provide customized genomics and imaging services for the pharmaceutical and biotechnology industry, with a specialized focus on oncology and neurodegenerative diseases.

• 

  Ambry Taps Former Medtronic Exec as New COO

  1/15/2018

  Mr. Le spent the last 14 years overseeing financial operations at Medtronic’s Diabetes Intensive Insulin Business Unit.

• Ambry Names Tom Schoenherr as Chief Commercial Officer

  12/14/2017

  Tom’s primary role will be to build upon Ambry’s success in the genetic testing space following the successful acquisition by Konica Minolta.

• Ambry Presents Research Expanding Our Understanding of Gene Disease Relationships at the San Antonio Breast Cancer Symposium

  12/6/2017

  Ambry Genetics (Ambry), a leading clinical genetics-testing lab, is presenting data this week at San Antonio Breast Cancer Symposium (SABCS) to help the medical community further understand the genetic mutations behind hereditary breast cancer, which accounts for up to 10% of all breast cancer diagnoses.

• Ambry Genetics’ Mitochondrial Disease Research May Help Develop Treatments Sooner

  11/28/2017

  The power of dedicated research, and discovery of new gene mutation variants help develop much-needed treatments.

• Intrepid Acts As Exclusive Financial Advisor to Ambry Genetics on Its Sale to Konica Minolta in a Deal Valued at US$1 Billion

  10/26/2017

  Intrepid Investment Bankers announced that it acted as the exclusive financial advisor to U.S.-based Ambry Genetics Corporation (Ambry) on its sale to Konica Minolta.